GB815877A - Improvements in or relating to bismuth salts - Google Patents
Improvements in or relating to bismuth saltsInfo
- Publication number
- GB815877A GB815877A GB1936357A GB1936357A GB815877A GB 815877 A GB815877 A GB 815877A GB 1936357 A GB1936357 A GB 1936357A GB 1936357 A GB1936357 A GB 1936357A GB 815877 A GB815877 A GB 815877A
- Authority
- GB
- United Kingdom
- Prior art keywords
- bismuth
- rutin
- mol
- water
- per cent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001621 bismuth Chemical class 0.000 title 1
- 229960004555 rutoside Drugs 0.000 abstract 10
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 abstract 6
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 abstract 6
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 abstract 6
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 abstract 6
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 abstract 6
- 235000005493 rutin Nutrition 0.000 abstract 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- 239000007864 aqueous solution Substances 0.000 abstract 3
- 229910052797 bismuth Inorganic materials 0.000 abstract 3
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 abstract 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 239000003513 alkali Substances 0.000 abstract 1
- -1 alkaline-earth metal salt Chemical class 0.000 abstract 1
- 229910021529 ammonia Inorganic materials 0.000 abstract 1
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- 229940049676 bismuth hydroxide Drugs 0.000 abstract 1
- TZSXPYWRDWEXHG-UHFFFAOYSA-K bismuth;trihydroxide Chemical compound [OH-].[OH-].[OH-].[Bi+3] TZSXPYWRDWEXHG-UHFFFAOYSA-K 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- RXPAJWPEYBDXOG-UHFFFAOYSA-N hydron;methyl 4-methoxypyridine-2-carboxylate;chloride Chemical compound Cl.COC(=O)C1=CC(OC)=CC=N1 RXPAJWPEYBDXOG-UHFFFAOYSA-N 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- VZZHAYFWMLLWGG-UHFFFAOYSA-K triazanium;bismuth;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [NH4+].[NH4+].[NH4+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O VZZHAYFWMLLWGG-UHFFFAOYSA-K 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/06—Benzopyran radicals
- C07H17/065—Benzo[b]pyrans
- C07H17/07—Benzo[b]pyran-4-ones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/94—Bismuth compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention comprises water-soluble bismuth-rutin compounds, especially compounds which contain about 1 gm. atom of bismuth to 1 gm. molecule of rutin, the preparation thereof by reacting an aqueous solution of a water-soluble complex or non-complex salt of bismuth with an aqueous suspension of rutin or an aqueous solution of an alkali or alkaline-earth metal salt of rutin, and pharmaceutical preparations containing bismuth-rutin compounds (see Group VI). In examples: (1) bismuth hydroxide (0.1 mol.), from bismuth nitrate and ammonia, is dissolved in acetic acid and mixed with a solution of rutin (0.1 mol.) in aqueous sodium hydroxide in an atmosphere of nitrogen, to yield a bismuth-rutin compound containing 31.38 per cent Bi; and (2) a suspension of rutin (0.1 mol.) in water is boiled with bismuth-ammonium citrate (0.4 mol.) to yield a bismuth-rutin compound containing 25.55 per cent Bi i.e. the bismuth-rutin compound contains about 1 gm. atom of bismuth to 1 gm. molecule of rutin).ALSO:The invention includes pharmaceutical compositions for external, parenteral or oral administration comprising a water-soluble bismuth-rutin compound (see Group IV (b)) together with a non-toxic pharmaceutical carrier. An example describes the preparation of a 5 per cent aqueous solution for injection.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEC13258A DE1003751B (en) | 1956-06-23 | 1956-06-23 | Process for the preparation of bismuth salts of oxyflavone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB815877A true GB815877A (en) | 1959-07-01 |
Family
ID=7015399
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB3611656A Expired GB797186A (en) | 1956-06-23 | 1956-11-26 | Improvements in or relating to bismuth salts |
| GB1936357A Expired GB815877A (en) | 1956-06-23 | 1957-06-19 | Improvements in or relating to bismuth salts |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB3611656A Expired GB797186A (en) | 1956-06-23 | 1956-11-26 | Improvements in or relating to bismuth salts |
Country Status (3)
| Country | Link |
|---|---|
| DE (1) | DE1003751B (en) |
| FR (1) | FR1160936A (en) |
| GB (2) | GB797186A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112494402B (en) * | 2020-12-22 | 2022-07-01 | 广东丸美生物技术股份有限公司 | Iris root extract and preparation method and application thereof |
-
1956
- 1956-06-23 DE DEC13258A patent/DE1003751B/en active Pending
- 1956-11-26 GB GB3611656A patent/GB797186A/en not_active Expired
- 1956-11-28 FR FR1160936D patent/FR1160936A/en not_active Expired
-
1957
- 1957-06-19 GB GB1936357A patent/GB815877A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE1003751B (en) | 1957-03-07 |
| GB797186A (en) | 1958-06-25 |
| FR1160936A (en) | 1958-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1433828A (en) | Molecular inclusion compounds | |
| GB1436978A (en) | Choline derivatives and pharmaceutical compositions containing the same | |
| GB815877A (en) | Improvements in or relating to bismuth salts | |
| GB1168391A (en) | Substituted Uracils | |
| US2681906A (en) | Pyridium penicillin | |
| GB1504862A (en) | Terpeno-phenoxyalkylamines | |
| US2397903A (en) | Methylene-bis-2 hydroxy-3 naphthoates | |
| IE34307B1 (en) | New 1-alkyl-6-azauracil compounds and preparations which contain a 1-alkyl-6-azauracil compound as an active ingredient | |
| GB1124441A (en) | Novel noralkaloids and process for preparing same | |
| GB967594A (en) | 2-(2,6-dimethyl-3-hydroxy-4-tert-butyl-benzyl)-2-imidazoline,and acid addition salts thereof,and process for their manufacture | |
| US2986571A (en) | Non-hygroscopic choline salt | |
| US2578536A (en) | Emetine penicillin | |
| GB1227190A (en) | ||
| GB1205094A (en) | Improvements in or relating to the treatment of hypertension | |
| GB1022935A (en) | Derivatives of dihydro-d-lysergic acid | |
| GB757137A (en) | New adrenochrome derivative and process for its production | |
| GB1173809A (en) | N-Substituted Nor-Morphines | |
| GB828642A (en) | New penicillin salts | |
| GB1318859A (en) | Imidazo-4,5-b-pyridine derivatives | |
| GB1017450A (en) | 2-amino-4-alkoxy-úË-triazines | |
| GB1124633A (en) | Manufacture of substituted thiadiazoles | |
| GB794738A (en) | Recovery of tetracycline from fermentation broths | |
| GB1088395A (en) | Improvements in or relating to sulphonyl urea derivatives | |
| US3159616A (en) | Novel salt of hydroxocobalamine | |
| GB1390524A (en) | Hydroxyquinoline derivative |